Robert Stöhr1, Vincent M Brandenburg2, Gunnar H Heine3, Micha T Maeder4, Gregor Leibundgut5, Alexander Schuh1, Urs Jeker6, Matthias Pfisterer7, Sandra Sanders-van Wijk8, Hans-Peter Brunner-la Rocca7,8. 1. Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Germany. 2. Department of Cardiology and Nephrology, Rhein-Maas Klinikum, Würselen, Germany. 3. AGAPLESION MARKUS KRANKENHAUS, Frankfurt am Main, Germany. 4. Department of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 5. Department of Internal Medicine, Cardiology, Kantonsspital Baselland, Liestal, Switzerland. 6. Heart Center, Luzerner Kantonsspital, Lucerne, Switzerland. 7. Department of Cardiology, University Hospital Basel, Basel, Switzerland. 8. Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands.
Abstract
AIM: Fibroblast growth factor 23 (FGF23) is an intensively studied biomarker at the crossroads of cardiovascular disease, heart failure (HF) and chronic kidney disease. Independent associations between increasing FGF23 levels and cardiovascular events were found in many, but not all studies. By analysing data from the TIME-CHF cohort, we sought to investigate the prognostic value of FGF23 in an elderly, multimorbid HF patient cohort. We determined differences between intact (iFGF23) and C-terminal FGF23 (cFGF23) regarding their prognostic value and their levels over time in different HF subgroups according to left ventricular ejection fraction (LVEF). METHODS AND RESULTS: In this multicentre trial of 622 patients with symptomatic HF aged ≥60 years, we determined iFGF23 and cFGF23 at baseline, 3, 6 and 12-month follow-up. In unadjusted analyses, cFGF23 significantly predicted all HF-related outcomes at all time points. The predictive value of iFGF23 was less and not statistically significant at baseline. After multivariable adjustments, the association between both cFGF23 and iFGF23 and outcome lost statistical significance apart from cFGF23 at month 3. Overall, patients with preserved and mid-range LVEF had higher levels of iFGF23 and cFGF23 than those with reduced LVEF. Levels decreased significantly during the first 3 months in mid-range and reduced LVEF patients, but did not significantly change over time in those with preserved LVEF. CONCLUSIONS: Fibroblast growth factor 23 is of limited value regarding risk prediction in this elderly HF population. Potentially heterogeneous roles of FGF23 in different LVEF groups deserve further investigation.
AIM: Fibroblast growth factor 23 (FGF23) is an intensively studied biomarker at the crossroads of cardiovascular disease, heart failure (HF) and chronic kidney disease. Independent associations between increasing FGF23 levels and cardiovascular events were found in many, but not all studies. By analysing data from the TIME-CHF cohort, we sought to investigate the prognostic value of FGF23 in an elderly, multimorbid HFpatient cohort. We determined differences between intact (iFGF23) and C-terminal FGF23 (cFGF23) regarding their prognostic value and their levels over time in different HF subgroups according to left ventricular ejection fraction (LVEF). METHODS AND RESULTS: In this multicentre trial of 622 patients with symptomatic HF aged ≥60 years, we determined iFGF23 and cFGF23 at baseline, 3, 6 and 12-month follow-up. In unadjusted analyses, cFGF23 significantly predicted all HF-related outcomes at all time points. The predictive value of iFGF23 was less and not statistically significant at baseline. After multivariable adjustments, the association between both cFGF23 and iFGF23 and outcome lost statistical significance apart from cFGF23 at month 3. Overall, patients with preserved and mid-range LVEF had higher levels of iFGF23 and cFGF23 than those with reduced LVEF. Levels decreased significantly during the first 3 months in mid-range and reduced LVEF patients, but did not significantly change over time in those with preserved LVEF. CONCLUSIONS:Fibroblast growth factor 23 is of limited value regarding risk prediction in this elderly HF population. Potentially heterogeneous roles of FGF23 in different LVEF groups deserve further investigation.
Authors: Juan B Ivey-Miranda; Brendan Stewart; Zachary L Cox; Wendy McCallum; Christopher Maulion; Olyvia Gleason; Grace Meegan; Jonathan G Amatruda; Julieta Moreno-Villagomez; Devin Mahoney; Jeffrey M Turner; F Perry Wilson; Michelle M Estrella; Michael G Shlipak; Veena S Rao; Jeffrey M Testani Journal: Circ Heart Fail Date: 2021-10-25 Impact factor: 8.790
Authors: Anne Cornelissen; Roberta Florescu; Kinan Kneizeh; Christian Cornelissen; Elisa Liehn; Vincent Brandenburg; Alexander Schuh Journal: J Clin Med Date: 2022-01-25 Impact factor: 4.241
Authors: Agata Zdanowicz; Szymon Urban; Barbara Ponikowska; Gracjan Iwanek; Robert Zymliński; Piotr Ponikowski; Jan Biegus Journal: J Pers Med Date: 2022-05-29
Authors: Prathap Kanagala; Jayanth R Arnold; Jamal N Khan; Anvesha Singh; Gaurav S Gulsin; Mohamed Eltayeb; Pankaj Gupta; Iain B Squire; Gerry P McCann; Leong L Ng Journal: ESC Heart Fail Date: 2020-09-16